Novo Nordisk's experimental obesity drug amycretin demonstrated promising weight loss results in an early-stage trial, with participants losing 22% of their body weight in 36 weeks. This news boosted ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Dr. Shamsheer Vayalil joined esteemed global leaders to discuss critical healthcare challenges posed by climate change ...

The Danish Embassy in Thailand, under the leadership of H.E. Mr. Danny Annan, Ambassador of Denmark to Thailand and Cambodia ...

Azzur Cleanrooms on Demand (COD) has entered this acronym-laden environment to provide cleanroom and laboratory spaces for so-called GxP manufacturing support. Opened in May 2023, it’s a 75,000-square ...

Four of our panelists discuss their favorite investments in the final installment of our 2025 stock-picking confab.

Novo Nordisk (NVO) was slammed by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure ...

Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American ...

Catch up on top health news including Novo Nordisk's new obesity treatment with promising weight loss results, Purdue Pharma's settlement on opioid crisis lawsuits, and the U.S. exit from the World ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The Pharmaceutical Technology Excellence Awards winners have been announced! Download our full 50+ page report to find out ...

The S&P 500 fell 0.1% in afternoon trading, a day after setting a record. The Dow Jones Industrial Average was down 46 points, or 0.1%, as of 12:47 p.m. Eastern time, and the Nasdaq composite fell 0.2 ...